Aptose Biosciences Inc. financial data

Symbol
APTO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
66 Wellington Street West, Suite 5300, Td Bank Tower Box 48, Toronto, Ontario, Canada
State of incorporation
Ontario, Canada
Fiscal year end
December 31
Former names
Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) (to 11/26/2014), LORUS THERAPEUTICS INC (to 9/2/2014), IMUTEC PHARMA INC (to 3/24/1998)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 102 % -71.7%
Debt-to-equity 1.93K % +4737%
Return On Equity -5.68K % -3613%
Return On Assets -280 % -156%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.1M shares +178%
Common Stock, Shares, Outstanding 18.1M shares +184%
Entity Public Float 29.6M USD -56.7%
Common Stock, Value, Issued 452M USD +3.01%
Weighted Average Number of Shares Outstanding, Basic 16.8M shares +169%
Weighted Average Number of Shares Outstanding, Diluted 16.8M shares +169%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.7M USD -15.3%
General and Administrative Expense 12.7M USD -21.9%
Nonoperating Income (Expense) 619K USD -55.6%
Net Income (Loss) Attributable to Parent -40.3M USD +15.3%
Earnings Per Share, Basic -4.49 USD/shares +42.6%
Earnings Per Share, Diluted -4.49 USD/shares +42.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.33M USD -0.83%
Cash, Cash Equivalents, and Short-term Investments 8.3M USD -64.4%
Other Assets, Current 593K USD +173%
Assets, Current 10.2M USD -59.8%
Property, Plant and Equipment, Net 34K USD -82.1%
Operating Lease, Right-of-Use Asset 756K USD -32.9%
Assets 10.9M USD -58.8%
Accounts Payable, Current 7.11M USD +103%
Employee-related Liabilities, Current 1.02M USD -37.8%
Accrued Liabilities, Current 5.2M USD -35.7%
Liabilities, Current 12.7M USD +6.17%
Operating Lease, Liability, Noncurrent 414K USD -49.3%
Liabilities 13.1M USD +2.63%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.32M USD -0.02%
Retained Earnings (Accumulated Deficit) -532M USD -8.19%
Stockholders' Equity Attributable to Parent -2.18M USD -116%
Liabilities and Equity 10.9M USD -58.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.3M USD +7.69%
Net Cash Provided by (Used in) Financing Activities 22.4M USD +1724%
Net Cash Provided by (Used in) Investing Activities 14.9M USD +96.7%
Common Stock, Shares, Issued 18.1M shares +184%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -70K USD +99.8%
Deferred Tax Assets, Valuation Allowance 91.3M USD +16.7%
Deferred Tax Assets, Gross 91.3M USD +16.7%
Operating Lease, Liability 818K USD -32.1%
Payments to Acquire Property, Plant, and Equipment 29K USD +20.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.3M USD +15.2%
Lessee, Operating Lease, Liability, to be Paid 884K USD -34.6%
Property, Plant and Equipment, Gross 801K USD -14.9%
Operating Lease, Liability, Current 404K USD +4.39%
Lessee, Operating Lease, Liability, to be Paid, Year Two 197K USD -57.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 462K USD +0.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 198K USD
Deferred Tax Assets, Operating Loss Carryforwards 73.6M USD +22.4%
Operating Lease, Payments 466K USD +5.43%
Additional Paid in Capital 82.3M USD +15.7%
Depreciation, Depletion and Amortization 62K USD -42.6%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.03M USD -55.5%